Relmada Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Cash Position: Relmada ended Q2 2026 with cash, cash equivalents, and short-term investments of $217.7 million, a significant increase from $93 million at the end of 2025. This funding is expected to support operations through 2029.

Expenses:

R&D Expenses: Increased to $8.4 million from $2.8 million year-over-year, primarily due to higher costs associated with NDV-01 and sepranolone studies.

G&A Expenses: Decreased to $6.6 million from $7.4 million, attributed to lower stock-based compensation.

Net Loss: Reported at $12.9 million, or $0.11 per share, compared to a net loss of $9.9 million or $0.30 per share in Q2 2025.

2Strategic Updates and Business Highlights

NDV-01 Development: A novel sustained-release formulation of gemcitabine and docetaxel targeting non-muscle-invasive bladder cancer (NMIBC).

Clinical Data: Phase II results showed a 95% complete response rate at any time and 76% durable response at 12 months.

Regulatory Pathway: FDA alignment on two registration pathways is confirmed, with plans to file the IND by the end of 2026 and initiate the Phase III RESCUE program upon clearance.

Sepranolone for Prader-Willi Syndrome: Development is complete, with an IND filing expected by year-end 2026.

Leadership Strengthening: Bipin Dalmia appointed as Chief Business Officer, bringing extensive experience in uro-oncology and manufacturing.

3Forward Guidance and Outlook

IND Filings: Both NDV-01 and sepranolone INDs are targeted for submission by the end of 2026.

Phase III Program: Ready to enroll patients immediately following IND clearance, with approximately 80 clinical sites prepared.

Financial Stability: Current cash resources are expected to support ongoing operations and clinical programs through 2029.

4Bad News, Challenges, or Points of Concern

Manufacturing Challenges: The need to secure manufacturing schedules with external partners (Piramal) poses potential delays. The complexity of scaling up to GMP standards is acknowledged as a critical hurdle.

Clinical Data Disclosure: Uncertainty around the timing of clinical data releases, particularly the 18-month data from Phase II, which may not be disclosed until 2027.

Increased Net Loss: The rise in net loss year-over-year raises concerns about operational efficiency and cost management.

5Notable Q&A Insights

Manufacturing Process: Management clarified that the formulation and process for NDV-01 are locked, and the focus is now on executing manufacturing activities. They emphasized that the remaining tasks are primarily logistical rather than technical.

FDA Input: No additional FDA input is required prior to IND filing once GMP batches are ready.

Clinical Trial Design: The primary endpoint for NDV-01 includes the highest response rate at any time, allowing for reinduction if patients do not respond initially.

Market Positioning: Bipin Dalmia highlighted the evolving NMIBC treatment landscape and the need for therapies that balance efficacy, durability, and safety, positioning NDV-01 as a potentially best-in-class option. Overall, Relmada Therapeutics is in a strong financial position with promising clinical developments, though it faces challenges in manufacturing and clinical data timelines that could impact its strategic objectives.